Literature DB >> 33977486

Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition.

Edward C Stites1.   

Abstract

This chapter will describe how mathematical modeling allows the RAS pathway to be studied with computational experiments. The mathematical model utilized simulates the biochemical reactions that regulate RAS signaling. This type of model incorporates knowledge of reaction mechanisms, including measured quantitative parameters that characterize these reactions for both wild-type and mutant RAS proteins. For an illustrative example, this chapter focuses on how modeling provided new insights that helped solve a problem that challenged the RAS community for nearly a decade: why do colorectal cancers with the KRAS G13D mutation, but not the other common KRAS mutations, benefit from EGFR inhibition? The methods described include computational dose-response experiments and the use of "computational chimeric" RAS mutants.

Entities:  

Keywords:  Computational biology; Systems biology; Systems pharmacology; Targeted therapy

Mesh:

Substances:

Year:  2021        PMID: 33977486      PMCID: PMC8639139          DOI: 10.1007/978-1-0716-1190-6_19

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  20 in total

1.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors:  Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal:  Nature       Date:  2012-01-26       Impact factor: 49.962

2.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

3.  Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.

Authors:  John C Hunter; Anuj Manandhar; Martin A Carrasco; Deepak Gurbani; Sudershan Gondi; Kenneth D Westover
Journal:  Mol Cancer Res       Date:  2015-06-02       Impact factor: 5.852

4.  Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

Authors:  Sabine Tejpar; Ilhan Celik; Michael Schlichting; Ute Sartorius; Carsten Bokemeyer; Eric Van Cutsem
Journal:  J Clin Oncol       Date:  2012-06-25       Impact factor: 44.544

5.  NMR-based functional profiling of RASopathies and oncogenic RAS mutations.

Authors:  Matthew J Smith; Benjamin G Neel; Mitsuhiko Ikura
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

6.  The response of cancers to BRAF inhibition underscores the importance of cancer systems biology.

Authors:  Edward C Stites
Journal:  Sci Signal       Date:  2012-10-16       Impact factor: 8.192

7.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

8.  Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGap interaction.

Authors:  Lothar Gremer; Bernd Gilsbach; Mohammad Reza Ahmadian; Alfred Wittinghofer
Journal:  Biol Chem       Date:  2008-09       Impact factor: 3.915

9.  Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D).

Authors:  Alessandro Palmioli; Elena Sacco; Cristina Airoldi; Federica Di Nicolantonio; Annalisa D'Urzo; Senji Shirasawa; Takehiko Sasazuki; Alessandro Di Domizio; Luca De Gioia; Enzo Martegani; Alberto Bardelli; Francesco Peri; Marco Vanoni
Journal:  Biochem Biophys Res Commun       Date:  2009-06-18       Impact factor: 3.575

10.  Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.

Authors:  Christian W Johnson; Yi-Jang Lin; Derion Reid; Jillian Parker; Spiro Pavlopoulos; Patrick Dischinger; Carrie Graveel; Andrew J Aguirre; Matthew Steensma; Kevin M Haigis; Carla Mattos
Journal:  Cell Rep       Date:  2019-08-06       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.